ZANVASTRO™ (zilganersen)

PRODUCT FACT SHEET

About ZANVASTRO (zilganersen)

ZANVASTRO is the first and only FDA-approved disease-modifying therapy for the treatment of Alexander disease (AxD) in pediatric and adult patients.[1]

- **AxD is an ultra-rare, genetic, progressive neurological disorder that is severely debilitating and often fatal.[2]**
- It occurs in approximately 1 per 1 to 3 million people worldwide.[2-6]
- AxD is caused by pathogenic variants (genetic changes that cause disease) in the glial fibrillary acidic protein *(GFAP)* gene, that lead to overproduction and toxic accumulation of GFAP within astrocytes (cells that support numerous important functions within the central nervous system).[3]
- It is generally characterized by progressive neurological deterioration that can result in loss of functional mobility and independence.[3]

ZANVASTRO is an RNA-targeted medicine that directly targets the underlying mechanism of AxD by reducing GFAP protein production in astrocytes with the potential to impact across domains affected by AxD[1].

ZANVASTRO is administered quarterly as an intrathecal injection.[1]

Please see Important Safety Information on Page 2. Please see full Prescribing Information for ZANVASTRO, also available at ZANVASTRO.com

ZANVASTRO Research at a Glance

The FDA approval of ZANVASTRO was based on positive data from the global, multicenter, randomized, double-blind, controlled, multiple-ascending dose (MAD) pivotal Phase 1-3 study of ZANVASTRO that enrolled 49 children and adults living with AxD.[1]

- ZANVASTRO demonstrated statistically significant and clinically meaningful stabilization on the primary efficacy endpoint of gait speed as assessed by the 10-Meter Walk Test compared to control at week 61 (mean difference 33.3%, p=0.041).[1]
- ZANVASTRO also showed improvement in gross motor function in patients aged 2 to 4 years as assessed by the Gross Motor Function Measure-88 compared to control at week 61 (mean difference 22.9).[1]

ZANVASTRO demonstrated a favorable safety and tolerability profile, with most adverse events (AEs) being mild or moderate in severity.[8] The most common adverse reactions with ZANVASTRO (incidence >25% patients treated with ZANVASTRO and greater than control) were vomiting, back pain, cough, headache, and post-lumbar puncture syndrome.[1]

US-ZLG-2600014 v1.0 09/26

Zanvastro™ (zilganersen)

Access to ZANVASTRO: Ionis Every Step™

Ionis is committed to helping people access the medicines they are prescribed and will offer a suite of services for people prescribed ZANVASTRO through Ionis Every Step. In addition to insurance support and financial assistance programs, Ionis Every Step offers personal support for patients. Ionis Patient Education Managers are dedicated partners for patients through every step of the treatment journey.

Visit ZANVASTRO.com for more information.

INDICATION

ZANVASTRO is indicated for the treatment of Alexander disease in pediatric and adult patients.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Aseptic Meningitis

If symptoms consistent with aseptic meningitis develop, diagnostic workup and treatment should be initiated according to the standard of care.

Adverse reactions of aseptic meningitis (also called chemical meningitis or drug-induced aseptic meningitis) were reported in patients treated with ZANVASTRO during the double-blind and open-label periods of Study 1. One patient experienced a serious adverse reaction of aseptic meningitis during the double-blind treatment period of Study 1, which reoccurred in the open-label extension period and required dose interruption and pretreatment with intravenous dexamethasone prior to subsequent administration of ZANVASTRO. Despite corticosteroid premedication, CSF white blood cell (WBC) and protein increased with continued exposure, but the patient remained asymptomatic and did not require discontinuation from treatment. In addition, nonserious adverse drug reactions of CSF WBC increases have also been reported with ZANVASTRO.

ADVERSE REACTIONS

Most common adverse reactions (incidence ≥25% patients treated with ZANVASTRO and greater than control) were vomiting, back pain, cough, headache, and post-lumbar puncture syndrome.

Patients Less Than 2 Years of Age

The adverse reactions of patients less than 2 years of age are expected to be similar to that of pediatric patients 2 years of age and older.

Please see full Prescribing Information for ZANVASTRO, also available at ZANVASTRO.com

References

1. ZANVASTRO. Prescribing Information. Ionis Pharmaceuticals. Carlsbad, CA: Ionis Pharmaceuticals, Inc.
2. National Organization for Rare Disorders. Alexander disease. https://rarediseases.org/rare-diseases/alexander-disease/. Accessed August 2026.
3. Messing A. Alexander disease. *Handb Clin Neurol.* 2018;148:693-700.
4. Yoshida T, Sasaki M, Yoshida M, et al. Nationwide survey of Alexander disease in Japan and proposed new guidelines for diagnosis. *J Neurol.* 2011;258(11):1998-2008.
5. Stellitano LA, Winstone AM, van der Knaap MS, Verity CM. Leukodystrophies and genetic leukoencephalopathies in childhood: a national epidemiological study. *Dev Med Child Neurol.* 2016;58(7):680-689.
6. Vanderver A, Hussey H, Schmidt JL, et al. Relative incidence of inherited white matter disorders in childhood to acquired pediatric demyelinating disorders. *Semin Pediatr Neurol.* 2012;19(4):219-223.
7. Data on file. Ionis Pharmaceuticals.
8. Waldman AT, Lynch DS, Tonduti D, et al. Efficacy and safety of zilganersen, an investigational RNA-targeted antisense therapy, in people living with Alexander disease: results from a pivotal study. Presented at: 2026 AAN Annual Meeting; April 18-22, 2026; Chicago, IL. Abstract 000941

US-ZLG-2600014 v1.0 09/26

Zanvastro™ (zilganersen)